Researchers from Northeastern University, in partnership with Novartis Institutes for Biomedical Research, wrote “Hyaluronic acid based self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors” for the April 2013 issue of Biomaterials. The scientists used Spectra/Por® dialysis membranes to dialyze a mixture of thiolated and PEGylated hyaluronic acid.
In this study, the researchers sought answers for multi drug resistant cancer treatments. They used a hyaluronic acid polymer as the building block for small interfering RNA (siRNA) drug delivery systems. The scientists successfully synthesized many possible hyaluronic acid building blocks for siRNA encapsulation.
Abstract: Anticancer therapeutics employing RNA interference mechanism holds promising potentials for sequence-specific silencing of target genes. However targeted delivery of siRNAs to tumor tissues and cells and more importantly, their intracellular release at sites of interest still remains a major challenge that needs to be addressed before this technique could become a clinically viable option. In the current study, we have engineered and screened a series of CD44 targeting hyaluronic acid (HA) based self-assembling nanosystems for targeted siRNA delivery. Click here to read the article.
Large-volume Process Dialysis is an emerging technology, driven by the increasing demand for gentle and consistent multi-batch purification at the production scale. While Laboratory Dialysis for research and analytical testing typically involves static stirring of small volumes for sample prep or solute release studies, Process Dialysis facilitates dynamic buffer flow around the membrane-encased sample to increase purification efficiency and improve large buffer handling for the production of fragile proteins, viscous fluids, and polymer gels, such as hyaluronic acid. Click here to learn more about Spectrum Process Dialysis.